Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00705874Phase 1Completed

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Role: lead

NCT00293488Phase 1Completed

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

Role: lead

NCT00585416Phase 2Terminated

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Role: collaborator

NCT00446654Phase 1Completed

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Role: lead

NCT00705653Phase 1Completed

Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

Role: lead

NCT00568308Phase 3Terminated

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

Role: lead

NCT00268593Phase 2Completed

Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer

Role: lead

All 7 trials loaded